Anzeige
Mehr »
Dienstag, 09.09.2025 - Börsentäglich über 12.000 News
Warum diese Aktie jetzt das perfekte Chance-Risiko-Profil für Investoren bietet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
102 Leser
Artikel bewerten:
(0)

PillSafe Launches SAFE Investment Opportunity to Advance the First Wireless Smart Prescription Bottle Technology System

Launch timetable is now imminent for developers of a revolutionary system for medication management as they open an initial SAFE investment round and will fund final product development and market validation in compelling use-case.

EDMOND, OK / ACCESS Newswire / September 9, 2025 / PillSafe, a leader in smart medication management technology, announces it will open an initial investment round via a SAFE offering, with a commercial launch in 2026. The patented solution secures prescriptions from pharmacy to medicine cabinet, addressing a $500+ billion problem in avoidable annual costs, medication nonadherence and controlled substance misuse in the U.S.

The raise supports two key initiatives: the next Phase of product development through MIDI, a venerable, award-winning medical device engineering firm, and for a payer-facing ROI model developed by PrecisionAQ the leader in health care economics, evidence generation and analytics. Remaining funds will go toward expanded IP filings, and to finalize FDA regulatory milestones.

Humanate Inc. is providing the AI interface for PillSafe using what it describes as "AI Agentic Avatars," that can speak over 100 languages. This AI component transforms PillSafe from a passive pill bottle into an interactive healthcare solution that adapts to patient behavior and provides coaching, creating long-term value for providers and payers.

These collaborators span best-in-class advanced medical device design firms, AI-based engagement platforms, manufacturing and packaging companies, regulatory experts, and payer strategy consultants. The model emphasizes partner specialization and scalability to keep costs low and improve time to market. The company plans to launch the product in 2026.

"PillSafe is a game-changer for controlled medications and adherence-critical prescriptions," said PillSafe CEO Jim Patton. "Our secure, connected dispensing system helps prevent addiction and overdose and monitors patient compliance thereby substantially reducing healthcare costs. We've built a team and product strategy that's ready for scale, and investors have an opportunity to support the first long-awaited, end-to-end solution with global impact."

The United States sees 352 million prescriptions annually for controlled substances and another 652 million for adherence-critical medications according to the MarketScan® Multi-State Medicaid Database. PillSafe addresses that dynamic with technology that locks access, monitors use, and alerts caregivers and clinicians to tampering or missed doses. The system is being engineered for FDA and HIPAA compliance and includes patient-friendly ergonomic features and built-in safeguards.

"PillSafe is the first product of its type in the world that provides wireless smart secure prescription bottles from the pharmacy to the home medicine cabinet," PillSafe COO Lon G. von Hurwitz said. "It's only now that we can provide a practical and scalable solution that supports patient safety, clinical integrity, and compliance."

Subject matter experts working directly with PillSafe emphasized the innovation's clinical, technological, and societal relevance:

Ross Maclean, MD, PhD, EVP, Head of Medical Affairs, PrecisionAQ:

"PillSafe will revolutionize patient monitoring for the dosages of controlled substances and adherent-critical medications through a highly coordinated system. From patient opt-in to the interactive in-home prescription dispensing extension, the process becomes much more manageable. AI and the interaction platform make it affordable, automated, and continuously overseen by the prescriber. PrecisionAQ will be working on quantifying the healthcare benefits and financial savings for the system as our role in this development."

Christopher Montalbano, Co-founder and CEO, MIDI Medical Product Development:

"MIDI is committed to helping PillSafe create the best innovation in prescription dispensing in 50+ years. The introduction of the Child Resistant cap occurred in 1967 which is when, our company was founded bringing the latest medical devices to the public. We aim to transform medication bottles into Smart, wirelessly connected mini-computers with functionalities that are only now feasible and highly anticipated by the healthcare industry."

Carlos Rodriguez, CEO and Co-Founder, HUMANATE, Inc:

"Humanate Inc, powered by NVIDIA, embodies the pinnacle of new AI-generated Agentic Avatars being set to work for PillSafe. Friendly, interactive, and comprehensively trained, they handle patient interactions for coaching, encouragement, and even mediating when prescribed routines or dosages are not followed. For the first time, this technology offers an affordable, valuable application for prescribers and caregivers, providing data when patients require personal support. By design, the system will constantly improve its methods and outcomes."

For more information, visit www.pillsafe.org

About PillSafe

PillSafe is a pioneering "smart" technology that shifts the standard of care in the pharmaceutical industry with in-home delivery of patient compliance in response to the opioid epidemic and adherence challenges. The company creates prescription compliance by restricting access to medication to only the patient/caregiver, keeping medication safe from divergence and abuse. PillSafe's "intelligent" design includes several innovative features that benefit the delivery network from the manufacturer to the pharmacy to the patient. The patented technology includes an electronic label that can increase adherence messaging, two-step verification, or active advertising from the manufacturer to the pharmacy to the patient.

Contact Information

Jessica Lombao
Customer Strategist
jessica.lombao@issuerdirect.com

.

SOURCE: PillSafe

Related Images



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/pillsafe-launches-safe-investment-opportunity-to-advance-the-first-wi-1068896

© 2025 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.